Elexacaftor Completed Phase 3 Trials for Cystic Fibrosis (CF) Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT03525444A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
NCT03525548A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)